Last reviewed · How we verify
TP regimen
TP regimen is a chemotherapy combination of docetaxel (Taxotere) and cisplatin that disrupts microtubule dynamics and DNA replication to kill cancer cells.
TP regimen is a chemotherapy combination of docetaxel (Taxotere) and cisplatin that disrupts microtubule dynamics and DNA replication to kill cancer cells. Used for Non-small cell lung cancer, Gastric cancer, Head and neck cancer.
At a glance
| Generic name | TP regimen |
|---|---|
| Also known as | Docetaxel, Cisplatin, Paclitaxel/Platinum |
| Sponsor | Tianjin Medical University Cancer Institute and Hospital |
| Drug class | Chemotherapy combination regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The TP regimen combines two cytotoxic agents: docetaxel, a taxane that stabilizes microtubules and prevents cell division, and cisplatin, a platinum-based alkylating agent that cross-links DNA and induces apoptosis. This combination targets rapidly dividing cancer cells through complementary mechanisms, enhancing overall cytotoxic effect compared to single-agent therapy.
Approved indications
- Non-small cell lung cancer
- Gastric cancer
- Head and neck cancer
- Breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Peripheral neuropathy
- Nephrotoxicity
- Alopecia
Key clinical trials
- Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (PHASE2)
- Clinical Research Study to Assess the Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis. (PHASE3)
- Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma (PHASE2)
- Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma (PHASE2)
- Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy (PHASE2)
- Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients (NA)
- A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] (PHASE2)
- AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TP regimen CI brief — competitive landscape report
- TP regimen updates RSS · CI watch RSS
- Tianjin Medical University Cancer Institute and Hospital portfolio CI